Search

30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's [...]

Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South [...]

Acclinate to provide community engagement support for Merck's oncology clinical trials. BIRMINGHAM, Ala., Nov. 30, 2023 /PRNewswire/ -- Acclinate, an expert in health equity through inclusive research, is collaborating with [...]

Third FDA Fast Track Designation Further Validates the Potential of REQORSA AUSTIN, Texas, June 28, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3907076-1&h=2171939742&u=https%3A%2F%2Fwww.genprex.com%2F&a=Genprex%2C+Inc.('Genprex' or the 'Company') (NASDAQ: GNPX), a clinical-stage gene therapy company focused [...]

NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere [...]

London based deal experts are the exclusive advisors for this and the ongoing partnering efforts for WM-A1-3389 LONDON, Feb. 8, 2023 /PRNewswire/ -- PharmaVentures is pleased to announce that it [...]

Industry influencers to tackle key issues, including eliminating travel obstacles for participants, optimizing travel budgets and more ORLANDO, Fla., Feb. 7, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3777504-1&h=3250857040&u=http%3A%2F%2Fbit.ly%2F3HjdlOD&a=Greenphire, the global leader in financial [...]

Wellmarker Bio is pleased to sign a clinical collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate a first-in-class treatment with a novel mechanism [...]

BASEL, Switzerland, Jan. 5, 2023 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into a clinical trial collaboration and [...]

SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that it has entered into a clinical trial [...]

HANGZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Hangzhou, Zhejiang, China, [December 9th, 2022], Zhejiang Doer Biologics Co., Ltd. ('Doer Bio'), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic [...]

Milestone payment to Dragonfly is triggered by dosing of first patient in Phase 1 clinical trial WALTHAM, Mass., Nov. 1, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ('Dragonfly'), today announced that [...]

-- Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab -- -- Data highlighted in late-breaking presentation at the European [...]

BERGEN, Norway, May 19, 2022 /PRNewswire/ -- Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that its investigational [...]

SHENZHEN, China, April 29, 2022 /PRNewswire/ -- Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., [...]

SEOUL, South Korea, March 3, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEOêÖCTO: Jisoo PaeêÖHansoo Park), a leading global microbiome anti-cancer drug development company, announced it has entered into [...]

DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last [...]

- FinancialNewsMedia.com News Commentary - PALM BEACH, Fla., Jan. 20, 2022 /PRNewswire/ -- Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of [...]

SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead [...]

- Study to Evaluate Intravenous Nemvaleukin in Combination With Pembrolizumab Compared to Investigator's Choice Chemotherapy - DUBLIN, Oct. 26, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation [...]

HOUSTON and SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it [...]

- IO Biotech to initiate a Phase 3 combination trial of IO102-IO103 and KEYTRUDA, which is designed to be potentially registrational for IO102-IO103 COPENHAGEN, Denmark, Sept. 14, 2021 /PRNewswire/ -- [...]

Anti-TNFR2 antibody targets Treg mediated immunosuppression Agreement supports the strong rationale for combining anti-TNFR2 and pembrolizumab in the ongoing Phase 1/2a trial BI-1808 is one of three BioInvent drug candidates [...]

U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration KENILWORTH, N.J., June 17, [...]

First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, [...]

SHANGHAI and ROCKVILLE, Md., May 26, 2021 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical [...]

DUBLIN, April 21, 2021 /PRNewswire/ -- The 'Disease Analysis: Dengue Vaccines' report has been added toResearchAndMarkets.com's offering. The dengue vaccines market is expected to expand rapidly following the anticipated launch [...]

TORONTO, April 15, 2020 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) - Portage Biotech Inc. ('Portage' or the 'Company') wishes to provide an update on a portfolio company, Intensity Therapeutics, [...]

First global clinical confirmation of a live biotherapeutic product (LBP) initiating a response in cancer patients LEEDS, England, March 17, 2020 /PRNewswire/ --4D pharma plc (AIM: DDDD), a pharmaceutical company [...]

- Data position the company to start potential registrational trials with two drugs in two tumor types COPENHAGEN, Denmark, Feb. 25, 2020 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company [...]

Wearable Devices Accurately Measure Heart Rate and Blood Pressure to Detect Drug Treatment Effects NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Koneksa Health, the leader in developing and implementing patient-focused [...]

LUND, Sweden, Dec. 18, 2019 /PRNewswire/ -- BioInvent International AB ('BioInvent' or the 'Company') (OMXS: BINV) today announces that it has entered into a clinical trial collaboration and supply agreement [...]

LEEDS, England, Nov. 6, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live Biotherapeutics, today announced preliminary safety and clinical observations from [...]

SAN FRANCISCO, Aug. 7, 2019 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) joins Merck in acknowledging the promising data from the KEYNOTE-522 trial. Merck recently announced that the Phase 3 [...]

- Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy - Promising [...]

COPENHAGEN, Denmark, May 15, 2019 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win technology, announced the initiation of the [...]

San Francisco's only Trauma 1 facility deploys the latest version of Agfa HealthCare Enterprise Imaging, validating the integrated single platform advantage MORTSEL, Belgium and GREENVILLE, South Carolina, November 23, 2018 [...]

- KEYNOTE-890 is the second 'KEYNOTE' study combining TAVO and KEYTRUDA SAN DIEGO and PENNINGTON, N.J., Oct. 15, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral [...]

-- Overall response rate of 40% with the bemcentinib/KEYTRUDA combination observed in AXL-positive, previously treated NSCLC patients, including PD-L1 negative patients who are not expected to benefit from KEYTRUDA monotherapy [...]

- Payment of $4M received for initiation of phase 1 trial - Up to additional $95 million for milestones plus royalties on sales LEXINGTON, Mass., Aug. 15, 2018 /PRNewswire/ -- [...]

Clinical response merits initiation of stage 2 of the Phase II combination trial 24 patients treated to date, 48 patients to be treated in total Responses will be correlated with [...]

DUBLIN, May 14, 2018 /PRNewswire/ -- The 'Market Spotlight: Polycystic Ovary Syndrome (PCOS)' report has been added toResearchAndMarkets.com's offering. This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising [...]

BERGEN, Norway , April 10, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors as a potential cornerstone of combination cancer therapy [...]

BERGEN, Norway, Feb. 19, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) announces that it has completed enrolment, ahead of schedule, of the planned 28 patients into the first stage of [...]

DUBLIN, Feb. 16, 2018 /PRNewswire/ -- The 'Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)' report has been added toResearchAndMarkets.com's offering. This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, [...]

- Results of this combination study were presented in a Spotlight Session (Spotlight Session 6: PD6-13) on December 7 WOODCLIFF LAKE, N.J., Dec. 8, 2017 /PRNewswire/ -- Eisai Inc. today [...]

NEW YORK, Oct. 12, 2017 /PRNewswire/ -- According to the latest announcement from CFDA, and Sinovac Beijing, the principal operation subsidiary of Sinovac Biotech (Nasdaq: SVA, 'Sinovac'), has accomplished its [...]

Initiation of a Phase 1/2 Combination Clinical Trial with Galinpepimut-S and KEYTRUDA (pembrolizumab) Across Various Indications Expected in 1H, 2018 HAMILTON, Bermuda and NEW YORK, Oct. 2, 2017 /PRNewswire/ -- [...]

HOUSTON, Nov. 1, 2016 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been treated in a multicenter Phase 2 [...]

Pivotal Data of the Targeted IL-23p19 Antibody to be Presented for the First Time at the 25th European Academy of Dermatology and Venereology (EADV) Congress MUMBAI, India and PRINCETON, N.J., [...]